Cellular targets of gefitinib

Dirk Brehmer, Zoltán Greff, Klaus Godl, Stephanie Blencke, Alexander Kurtenbach, Martina Weber, Stefan Müller, Bert Klebl, Matt Cotten, György Kéri, Josef Wissing, Henrik Daub

Research output: Contribution to journalArticle

162 Citations (Scopus)


Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.

Original languageEnglish
Pages (from-to)379-382
Number of pages4
JournalCancer Research
Issue number2
Publication statusPublished - Jan 15 2005


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Weber, M., Müller, S., Klebl, B., Cotten, M., Kéri, G., Wissing, J., & Daub, H. (2005). Cellular targets of gefitinib. Cancer Research, 65(2), 379-382.